When administered subcutaneously, it was found to increase glucose-dependent insulin secretion, suppression of pp high glucagon concentration, delayed gastric emptying, inhibition of food intake, modulation of glucose trafficking in peripheral tissues and wt loss with mild to moderate hypoglycemia and gastrointestinal adverse effects. Here, INS is linked to Hypoglycemia.